THE ORAL PROTEASOME INHIBITOR IXAZOMIB IN COMBINATION WITH MELPHALAN-PREDNISONE FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 1/2 DOSE-ESCALATION STUDY (NCT01335685)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA20020T8" target="_blank" >RIV/61988987:17110/17:A20020T8 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
THE ORAL PROTEASOME INHIBITOR IXAZOMIB IN COMBINATION WITH MELPHALAN-PREDNISONE FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 1/2 DOSE-ESCALATION STUDY (NCT01335685)
Original language description
Bortezomib-melphalan-prednisone (VMP) is a standard-of-care regimen for elderly NDMM patients. Whereas bortezomib is administered intravenously or subcutaneously, ixazomib is an oral proteasome inhibitor with a safety profile amenable to extended dosing.
Czech name
—
Czech description
—
Classification
Type
D - Article in proceedings
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Article name in the collection
HAEMATOLOGICA
ISBN
—
ISSN
0390-6078
e-ISSN
—
Number of pages
2
Pages from-to
111-112
Publisher name
FERRATA STORTI FOUNDATION, VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
Place of publication
PAVIA, ITALY
Event location
Španělsko
Event date
Jan 1, 2017
Type of event by nationality
EUR - Evropská akce
UT code for WoS article
000404127001234